Financial Performance - Taysha Gene Therapies reported a net loss of $20.9 million, or $0.09 per share, for Q2 2024, compared to a net loss of $24.6 million, or $0.38 per share, in Q2 2023[5]. - Research and development expenses decreased to $15.1 million in Q2 2024 from $19.8 million in Q2 2023, primarily due to a milestone fee in the prior year[4]. - General and administrative expenses increased to $7.3 million in Q2 2024 from $6.0 million in Q2 2023, driven by higher stock-based compensation and consulting fees[5]. - The accumulated deficit widened from $(513,007,000) to $(557,996,000), indicating ongoing investment in growth despite losses[14]. Cash and Assets - Cash and cash equivalents as of June 30, 2024, were $172.7 million, providing a runway into Q4 2026[5]. - Total current assets as of December 31, 2023, amount to $149,868,000, with cash and cash equivalents at $143,940,000[12]. - Total assets increased from $172,731,000 to $200,393,000, indicating a strong growth trajectory[14]. - The company holds $2,000,000 in assets held for sale, indicating potential divestitures or restructuring[12]. - The company has $449,000 in restricted cash, which may be earmarked for specific future obligations[12]. Liabilities and Equity - Total liabilities decreased from $97,794,000 to $91,525,000, reflecting a reduction in current liabilities from $36,756,000 to $34,176,000[13]. - Stockholders' equity increased significantly from $74,937,000 to $108,868,000, driven by an increase in additional paid-in capital from $587,942,000 to $664,457,000[14]. - Deferred revenue decreased from $18,106,000 to $13,583,000, suggesting a potential shift in revenue recognition[13]. - Operating lease liabilities remain stable, with a slight decrease in the current portion from $18,953,000 to $18,134,000[13]. Clinical Trials and Developments - TSHA-102 was generally well tolerated with no serious adverse events reported in both pediatric and adolescent/adult trials[2]. - Dosing of the second patient in the high dose cohort of the adolescent/adult trial is scheduled for Q3 2024[4]. - Safety and efficacy data from cohort two (n=3) and updates from cohort one (n=2) are expected in the first half of 2025[4]. - The pediatric trial has received clearance to expand into Canada, enhancing the study's geographical reach[3]. - Taysha aims to report clinical data from both high and low dose cohorts in the first half of 2025, focusing on further informing regulatory discussions[2]. Capital Raising - The company completed a public follow-on offering with total net proceeds of $76.8 million[3]. - The increase in common stock issued from 186,960,193 to 201,381,450 shares reflects ongoing capital raising efforts[14].

Core Insights - Taysha Gene Therapies, Inc. reported promising preliminary data from its TSHA-102 clinical program for Rett syndrome, showing durable improvements and a favorable safety profile in both adult and pediatric patients [1][2][4] - The company successfully dosed the first patient in the high dose cohort of its adolescent/adult trial and received approval to proceed with additional dosing in both adolescent/adult and pediatric trials [1][2][5] - Taysha completed a public follow-on offering, raising $76.8 million, which extends its cash runway into Q4 2026 [1][3][10] Clinical Program Updates - TSHA-102 demonstrated sustained improvements in clinical domains such as motor skills and communication in patients from cohort one of the trials [4][6] - The first patient in cohort two (high dose) was dosed, and initial assessments indicated no serious adverse events or dose-limiting toxicities [5][6] - Data from both cohorts of the adolescent/adult and pediatric trials are expected in the first half of 2025 [1][7] Financial Highlights - Research and development expenses decreased to $15.1 million in Q2 2024 from $19.8 million in Q2 2023, primarily due to a prior milestone fee [8] - General and administrative expenses increased to $7.3 million in Q2 2024 from $6.0 million in Q2 2023, attributed to higher stock-based compensation and consulting fees [9] - The net loss for Q2 2024 was $20.9 million, or $0.09 per share, compared to a net loss of $24.6 million, or $0.38 per share, in Q2 2023 [10][16] Cash Position - As of June 30, 2024, Taysha had $172.7 million in cash and cash equivalents, supporting operations into Q4 2026 [10][17] Company Overview - Taysha Gene Therapies focuses on AAV-based gene therapies for severe monogenic diseases, with TSHA-102 as its lead program targeting Rett syndrome [12][14] - The company has received multiple designations from regulatory authorities, including Regenerative Medicine Advanced Therapy and Fast Track designations from the FDA [12]

DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinicalstage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972,221 shares of ...

Taysha Gene Therapies (NASDAQ:TSHA) stock is taking a beating on Wednesday after the gene therapy company announced a proposed public offering for its shares. What we do know is that it also intends to offer pre-funded warrants for certain investors. On top of that, underwriters have a 30-day option to acquire an additional 15% of shares included in the offering. How This Affects TSHA Stock On top of that, the pricing of the offering may upset investors. It's expected to be discounted compared to the compan ...

Exhibit 99.2 We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical ...

Core Viewpoint - Taysha Gene Therapies, Inc. has initiated an underwritten public offering of up to $75 million in common stock and pre-funded warrants, subject to market conditions [1][2]. Company Overview - Taysha Gene Therapies is a clinical-stage biotechnology company focused on AAV-based gene therapies for severe monogenic diseases of the central nervous system [6]. - The company's lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies [6]. - Taysha aims to address severe unmet medical needs and improve the lives of patients and caregivers through transformative medicines [6]. Offering Details - The public offering includes a 30-day option for underwriters to purchase an additional 15% of the shares offered [1]. - Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering, with Cantor also serving as a book-running manager [2].

Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering, and Cantor is also serving as a book-running manager for the proposed offering. About Taysha Gene Therapies time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law. DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinicalstage biotechnology ...

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity Initial data from first two pediatric patients showed improvements across multiple efficacy measures and clinical domains, with early evidence of developmental gains (patient one: impro ...

Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time Date/Time: Tuesday, June 18, 2024, at 8:00 AM Eastern Time Registration: https://lifescievents.com/event/taysha-2/ The live webcast and replay will be available through Taysha's website here. About Taysha Gene Therapies Media Contact: Carolyn Hawley Taysha-Hosted Webcast Details Oral Presentation Title: TSHA-102 gene therapy for Rett syndrome: First-cohort data from the REVEAL Adolescent/Adult and Pediatric studies Date/Time: Wednesd ...

DALLAS, June 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinicalstage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 3, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 360,000 shares of the Company's common stock in connection with their employment. The ...